در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Efficacy,Gastric cancer,EOX,m-DCF,safety
- چکیده:
- چکیده انگلیسی: Introduction: One of the major challenges of advanced gastric cancer treatment is the lack of a standard regimen for patients. However, several clinical trials have shown that modified docetaxel, cisplatin, and 5-fluorouracil (m-DCF) and epirubicin, oxaliplatin, and capecitabine (EOX) regimens are superior to other regimens. Methods: This randomized, single-center clinical trial was performed on 40 patients with advanced gastric cancer. The first group received the m-DCF regimen as follows: docetaxel (40 mg/m2) on the first day; cisplatin (40 mg/m2) on the first and second days; and 5-fluorouracil (400 mg/m2) from the first to fourth day. The second group received the EOX regimen, including epirubicin (50 mg/m2) and oxaliplatin (130 mg/m2) i.v on the first day and capecitabine at a twice-daily dose of 625 mg/m2 p.o for 21 days. Treatment was applied every three weeks for a total of eight cycles in both groups. In each group, the overall and progression-free survival rates and toxicity were assessed. Results: A total of 40 patients were enrolled in this study (21 samples in the m-DCF group and 19 samples in the EOX group), 62.5% of whom were male. The median survival rate was 14.00 (95% CI: 11.82-16.18) months in the m-DCF group and 15.00 (95% CI: 9.56-20.43) months in the EOX group; however, differences between the groups were not significant. The progression-free survival rate was higher in the EOX group, although there was no significant difference between the two groups. Also, there was no significant difference regarding the side effects (e.g., toxicity) or need for supportive care between the groups. Conclusion: It seems that both m-DCF and EOX regimens are similar in terms of survival and toxicity and are recommended as first-line treatment for advanced gastric cancer with respect to the patient’s status.
- انتشار مقاله: 17-08-1398
- نویسندگان: Ahmad Ahmadzadeh,Seyed Saeid Seyedian,Armita Valizadeh,Mahin Soleimani,Pedram Nazari,Hossein Hamidi
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: JC Virus,colorectal adenocarcinoma,Polymerase Chine Reaction
- چکیده:
- چکیده انگلیسی: Colorectal cancer is the most repetitious malignancies with high mortality worldwide. JC virus (JCV) is ubiquitous
Polyomavirus, with seroprevalence rates ranging from 70% to 90% in adult population. Recently the role of JCV have
been reported in many malignant tumors worldwide. The association of JCV was reported in patients with colon and
rectum cancers. Thus this study was conducted to evaluate the association of JCV DNA in patients with colon cancer
type Adenocarcinoma. Material and Methods: A total of 120 formalin-fixed paraffin-embedded tissue blocks samples
were collected including 20/40(50%) males, 20/40(50%) females patients with Colorectal Cancer(CRC), and 80 (50%
males, 50% females) patients with benign tumor as a control. DNA was extracted for all the samples. Nested PCR was
carried out for detection of Vp1/T-Ag junction genome in JCV genome by Nested-PCR assay. Randomly, PCR products
of 6 samples were sequenced to analysis the partial JCV DNA. The phylogeny tree was constructed to determine
homology identity with other JCV. Results: 4/40(10%) samples of test group and 10/80 (12.5%) of control samples
were positive for JCV DNA (P= 0.69). Out of 4 samples positive for JC DNA, 3(7.5%) were males and 1(2.4%) female
(P=0.29). The frequency of JCV DNA in age group> 50 years was 4/32(10%), while in age group (0%) (p= 0.29). Conclusion: prevalence of JCV DNA was among 10% patients with CRC and 12.5% benign tumors
(p=0.69). The distribution of JCV DNA was among 7.5% male and 2.5% female (p= 0.29). The frequency of JCV
DNA was among 10% cases of age group >50 years and 0% of age group protein expression might explain the increased risk of colorectal cancer and requires further investigation.- انتشار مقاله: 08-07-1397
- نویسندگان: Azadeh Haghi Navand,Ali Teimoori,Manoochehr Makvandi,Nilofar Nisi,Seyed Saeid Seyedian,Nastaran Ranjbari,Kambiz Ahmadi Angali,Hadis Keyani,Maryam Tabasi,Keyvan Pourjabari
- مشاهده